Literature DB >> 22474248

C/EBPα and DEK coordinately regulate myeloid differentiation.

Rositsa I Koleva1, Scott B Ficarro, Hanna S Radomska, Marlene J Carrasco-Alfonso, John A Alberta, James T Webber, C John Luckey, Guido Marcucci, Daniel G Tenen, Jarrod A Marto.   

Abstract

The transcription factor C/EBPα is a critical mediator of myeloid differentiation and is often functionally impaired in acute myeloid leukemia. Recent studies have suggested that oncogenic FLT3 activity disrupts wild-type C/EBPα function via phosphorylation on serine 21 (S21). Despite the apparent role of pS21 as a negative regulator of C/EBPα transcription activity, the mechanism by which phosphorylation tips the balance between transcriptionally competent and inhibited forms remains unresolved. In the present study, we used immuno-affinity purification combined with quantitative mass spectrometry to delineate the proteins associated with C/EBPα on chromatin. We identified DEK, a protein with genetic links to leukemia, as a member of the C/EBPα complexes, and demonstrate that this association is disrupted by S21 phosphorylation. We confirmed that DEK is recruited specifically to chromatin with C/EBPα to enhance GCSFR3 promoter activation. In addition, we demonstrated that genetic depletion of DEK reduces the ability of C/EBPα to drive the expression of granulocytic target genes in vitro and disrupts G-CSF-mediated granulocytic differentiation of fresh human BM-derived CD34(+) cells. Our data suggest that C/EBPα and DEK coordinately activate myeloid gene expression and that S21 phosphorylation on wild-type C/EBPα mediates protein interactions that regulate the differentiation capacity of hematopoietic progenitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22474248      PMCID: PMC3367892          DOI: 10.1182/blood-2011-10-383083

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  p300 coactivates the adipogenic transcription factor CCAAT/enhancer-binding protein alpha.

Authors:  R L Erickson; N Hemati; S E Ross; O A MacDougald
Journal:  J Biol Chem       Date:  2001-05-11       Impact factor: 5.157

2.  Transcriptional activation by AP-2alpha is modulated by the oncogene DEK.

Authors:  Mónica Campillos; Miguel Angel García; Fernando Valdivieso; Jesús Vázquez
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

3.  Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells.

Authors:  Jörg Cammenga; James C Mulloy; Francisco J Berguido; Donal MacGrogan; Agnes Viale; Stephen D Nimer
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

4.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.

Authors:  T Pabst; B U Mueller; P Zhang; H S Radomska; S Narravula; S Schnittger; G Behre; W Hiddemann; D G Tenen
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

5.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

6.  C/EBPalpha and G-CSF receptor signals cooperate to induce the myeloperoxidase and neutrophil elastase genes.

Authors:  W Wang; X Wang; A C Ward; I P Touw; A D Friedman
Journal:  Leukemia       Date:  2001-05       Impact factor: 11.528

7.  CREB (cAMP response element binding protein) and C/EBPalpha (CCAAT/enhancer binding protein) are required for the superstimulation of phosphoenolpyruvate carboxykinase gene transcription by adenoviral E1a and cAMP.

Authors:  J M Routes; L A Colton; S Ryan; D J Klemm
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

Review 8.  The roles of FLT3 in hematopoiesis and leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 9.  Disruption of differentiation in human cancer: AML shows the way.

Authors:  Daniel G Tenen
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

10.  Chromatin immunoprecipitation (ChIP) studies indicate a role for CCAAT enhancer binding proteins alpha and epsilon (C/EBP alpha and C/EBP epsilon ) and CDP/cut in myeloid maturation-induced lactoferrin gene expression.

Authors:  Arati Khanna-Gupta; Theresa Zibello; Hong Sun; Peter Gaines; Nancy Berliner
Journal:  Blood       Date:  2003-01-09       Impact factor: 22.113

View more
  31 in total

1.  Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias.

Authors:  Maroun Karam; Morgan Thenoz; Valérie Capraro; Jean-Philippe Robin; Christiane Pinatel; Agnès Lancon; Perrine Galia; David Sibon; Xavier Thomas; Sophie Ducastelle-Lepretre; Franck Nicolini; Mohamed El-Hamri; Youcef Chelghoun; Eric Wattel; Franck Mortreux
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

Review 2.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

3.  Proteomic analysis demonstrates activator- and chromatin-specific recruitment to promoters.

Authors:  Timothy W Sikorski; Yoo Jin Joo; Scott B Ficarro; Manor Askenazi; Stephen Buratowski; Jarrod A Marto
Journal:  J Biol Chem       Date:  2012-08-17       Impact factor: 5.157

4.  Intercellular trafficking of the nuclear oncoprotein DEK.

Authors:  Anjan K Saha; Ferdinand Kappes; Amruta Mundade; Anja Deutzmann; David M Rosmarin; Maureen Legendre; Nicolas Chatain; Zeina Al-Obaidi; Barbara S Adams; Hidde L Ploegh; Elisa Ferrando-May; Nirit Mor-Vaknin; David M Markovitz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

5.  DEK over-expression promotes mitotic defects and micronucleus formation.

Authors:  Marie C Matrka; Robert F Hennigan; Ferdinand Kappes; Monica L DeLay; Paul F Lambert; Bruce J Aronow; Susanne I Wells
Journal:  Cell Cycle       Date:  2015-05-06       Impact factor: 4.534

6.  Loss of DEK induces radioresistance of murine restricted hematopoietic progenitors.

Authors:  Juana Serrano-Lopez; Kalpana Nattamai; Nicholas A Pease; Miranda S Shephard; Ashley M Wellendorf; Mathieu Sertorio; Eric A Smith; Hartmut Geiger; Susanne I Wells; Jose A Cancelas; Lisa M Privette Vinnedge
Journal:  Exp Hematol       Date:  2017-12-27       Impact factor: 3.084

7.  C/EBPα regulates osteoclast lineage commitment.

Authors:  Wei Chen; Guochun Zhu; Liang Hao; Mengrui Wu; Hongliang Ci; Yi-Ping Li
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-11       Impact factor: 11.205

8.  Tandem Affinity Purification and Mass Spectrometry (TAP-MS) for the Analysis of Protein Complexes.

Authors:  Guillaume Adelmant; Brijesh K Garg; Maria Tavares; Joseph D Card; Jarrod A Marto
Journal:  Curr Protoc Protein Sci       Date:  2019-02-01

Review 9.  C/EBPα in normal and malignant myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490

10.  The DEK Oncoprotein Is a Critical Component of the EKLF/KLF1 Enhancer in Erythroid Cells.

Authors:  Felix Lohmann; Mohan Dangeti; Shefali Soni; Xiaoyong Chen; Antanas Planutis; Margaret H Baron; Kyunghee Choi; James J Bieker
Journal:  Mol Cell Biol       Date:  2015-08-24       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.